Related Experiment Videos
Bioavailability and pharmacokinetic studies of eurycomanone from Eurycoma longifolia
Bin-Seng Low1, Bee-Hong Ng, Wai-Peng Choy
1School of Pharmaceutical Sciences, University Sains Malaysia, Penang, Malaysia.
Planta Medica
|October 6, 2005
Summary
Eurycomanone, a compound from Eurycoma longifolia Jack, shows poor oral bioavailability in rats. This suggests potential challenges for oral drug delivery due to low absorption or high first-pass metabolism.
Area of Science:
- Pharmacology and Pharmacokinetics
- Natural Product Analysis
- Drug Metabolism
Background:
- Eurycoma longifolia Jack extract contains eurycomanone, a bioactive quassinoid with potential therapeutic applications.
- Understanding the pharmacokinetic profile of eurycomanone is crucial for its effective utilization.
- Previous studies have not fully elucidated the oral bioavailability of eurycomanone.
Purpose of the Study:
- To develop and validate a High-Performance Liquid Chromatography (HPLC) method for quantifying eurycomanone in rat plasma.
- To determine the pharmacokinetic parameters and oral bioavailability of eurycomanone following intravenous and oral administration of Eurycoma longifolia Jack extract.
- To investigate potential reasons for poor oral bioavailability, such as membrane permeability and first-pass metabolism.
Main Methods:
- Development and validation of an HPLC assay for eurycomanone in rat plasma.
- Intravenous and oral administration of Eurycoma longifolia Jack extract to rats.
- Pharmacokinetic analysis including determination of Cmax, Tmax, AUC, half-life, clearance, and volume of distribution.
- Calculation of absolute oral bioavailability.
Main Results:
- Eurycomanone was detected in rat plasma after both administration routes.
- Intravenous administration resulted in higher plasma concentrations compared to oral administration.
- Absolute oral bioavailability was determined to be low (10.5%), with a long Tmax (4.40 h) and low Cmax (0.33 microg/mL).
- Eurycomanone exhibited a high volume of distribution (0.68 L/kg), suggesting distribution into extravascular fluids.
- Eurycomanone stability was confirmed under various pH conditions.
Conclusions:
- Eurycomanone demonstrates poor oral bioavailability in rats, likely due to poor membrane permeability and/or significant first-pass metabolism.
- The validated HPLC method provides a reliable tool for future pharmacokinetic studies of eurycomanone.
- Further research is warranted to explore strategies to enhance the oral absorption and efficacy of eurycomanone.